Ironwood Pharmaceuticals, Inc. - Class A
IRWDStock
$3.87+479.71%52W
Market Cap$635.41M
P/E26.46x
Div yield—
Beta0.21
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-11.42%
Price vs S&P 500 (4W)8.69%
VGM Score66.28
Market Capitalization$635.41M
P/E Ratio (Annual)26.46x
Earnings Surprise History
Q1 260.24est. 0.24
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.90
3.90
3.90
3.90
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IRWDIronwood Pharmaceuticals, Inc. - Class A | A | C | B | $3.87 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Ironwood Pharmaceuticals is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. The company markets LINZESS and CONSTELLA (both linaclotide) for the treatment of irritable bowel syndrome with constipation, chronic constipation, and functional constipation across North America, Europe, and Asia-Pacific regions.